COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA

被引：0
|
作者：
Kim, Y. G. [1 ]
Lee, E. K. [1 ]
机构：
[1] SookMyung Womens Univ, Seoul, South Korea
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)73117-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A514 / A514
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
    Zhou, Dongchu
    Luo, Xia
    Zhou, Zhen
    Zeng, Xiaohui
    Wan, Xiaomin
    Tan, Chongqing
    Liu, Qiao
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [2] COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR
    Freire, V
    Cabezas, M.
    Salcedo, E.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S30 - S31
  • [3] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    [J]. Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [4] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
  • [5] A Cost-Effectiveness Analysis of Docetaxel in the Second-Line Treatment of Non-Small Cell Lung Cancer
    Jeremy Holmes
    David Dunlop
    Lindsay Hemmett
    Peter Sharplin
    Uday Bose
    [J]. PharmacoEconomics, 2004, 22 : 581 - 589
  • [6] Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer A Real-World Cost-Effectiveness Analysis
    Cromwell, Ian
    van der Hoek, Kimberly
    Melosky, Barbara
    Peacock, Stuart
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (12) : 2097 - 2103
  • [7] Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer
    Chouaid, C.
    Moser, A.
    Coudray-Omnes, C.
    Vergnenegre, A.
    [J]. REVUE DES MALADIES RESPIRATOIRES, 2008, 25 (09) : 1096 - 1103
  • [8] Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France
    Marine, Sivignon
    Stephane, Roze
    Nicolas, Plommet
    Felizzi, Federico
    Paracha, Noman
    Benjamin, Mazaleyrat
    Perol, Maurice
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (05) : 464 - 473
  • [9] Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China
    Shi, Yafei
    Chen, Wei
    Zhang, Yujun
    Bo, Mingming
    Li, Chunyu
    Zhang, Mingyu
    Li, Guohui
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (18)
  • [10] Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer in the Era of Personalized Medicine
    Biswas, Bivas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (05) : 524 - 524
12345